Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Fortress Biotech's Enterprise Value is €78.80 Mil.
Fortress Biotech's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €136.52 Mil. Therefore, Fortress Biotech's EV-to-FCF for today is 0.58.
The historical rank and industry rank for Fortress Biotech's EV-to-FCF or its related term are showing as below:
STU:CNB1'
s EV-to-FCF Range Over the Past 10 Years
Min: -4.2 Med: -1.06 Max: 0.18
Current: -0.33
During the past 13 years, the highest EV-to-FCF of Fortress Biotech was 0.18. The lowest was -4.20. And the median was -1.06.
STU:CNB1's EV-to-FCF is ranked better than 99.7% of 338
companies
in the Biotechnology industry
Industry Median: 15.02
vs STU:CNB1: -0.33
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Fortress Biotech's PE Ratio (TTM) for today is calculated as:
Fortress Biotech's share price for today is €1.93.
Fortress Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.484.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Fortress Biotech EV-to-FCF Related Terms
Fortress Biotech EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Fortress Biotech's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Fortress Biotech's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fortress Biotech EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fortress Biotech's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Fortress Biotech's EV-to-FCF falls into.
Fortress Biotech's current Enterprise Value is €78.80 Mil.
Fortress Biotech's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €136.52 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fortress Biotech (STU:CNB1) has a EV-to-FCF of 0.58 as of Jul. 21, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Fortress Biotech and its competitors. According to the industry distribution chart, Fortress Biotech ranks #1 out of 338 companies in the Biotechnology industry, placing it in the top 0.3%.
Is Fortress Biotech's EV-to-FCF too high?
Fortress Biotech's current EV-to-FCF is 0.58. The Biotechnology industry median EV-to-FCF is 15.02. Fortress Biotech's value of 0.58 is 96.1% below this industry median. Based on the distribution chart, Fortress Biotech ranks #1 out of 338 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Fortress Biotech has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does Fortress Biotech's EV-to-FCF compare to RLYB and INO?
According to the Biotechnology industry distribution chart, Fortress Biotech ranks #1 out of 338 companies for EV-to-FCF. This places Fortress Biotech in the top 0% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 15.02. Fortress Biotech's value of 0.58 is 96.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.02, based on 338 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fortress Biotech's current EV-to-FCF of 0.58 is 96.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Fortress Biotech and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fortress Biotech's current EV-to-FCF is 0.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fortress Biotech stock overvalued right now?
Fortress Biotech (STU:CNB1) has a current EV-to-FCF of 0.58. The stock's GF Value™ is €0.73, compared to a current price of €1.93 — trading 164.4% above its estimated fair value. The current EV-to-FCF is 0.58 and 96.1% below the Biotechnology industry median of 15.02. Fortress Biotech's overall GF Score™ is 44/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Fortress Biotech (STU:CNB1), the current EV-to-FCF is 0.58 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fortress Biotech (STU:CNB1) Overvalued in 2026?
Based on GuruFocus' analysis, Fortress Biotech stock appears to be overvalued.
The current stock price of €1.93 is trading 164.4% above its estimated GF Value™ of €0.73.
Key valuation signals for STU:CNB1:
EV-to-FCF: 0.58
GF Value™: €0.73 vs. price of €1.93 (164.4% above fair value)
Industry Position: 96.1% below the Biotechnology median (#1 of 338)
No single metric tells the full story. See the STU:CNB1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development.
44GF Score
Get the complete analysis for STU:CNB1
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:CNB1 has been successfully added to your 
